Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies. | UCSF Helen Diller Family Comprehensive Cancer Center

Author List

Manabe T, Bergo HC, Li Q, Wang TS, Severson P, Miller N, Lee C, Yay Donderici E, Zhang N, Wu W, Chou YT, Kerr DL, Allegakoen P, Grandinetti KB, Soroceanu L, Pelham RJ, Martin ES, Murphy EA, Khanna V, Neal JW, Chen CT, Kato S, Williams R, Bivona TG

Publication

Nature communications

Publication ID (Profile URL)

https://researcherprofiles.org/profile/754171959

Publication Year

2026

PubMed ID

41654519

Publication Title

Manabe T, Bergo HC, Li Q, Wang TS, Severson P, Miller N, Lee C, Yay Donderici E, Zhang N, Wu W, Chou YT, Kerr DL, Allegakoen P, Grandinetti KB, Soroceanu L, Pelham RJ, Martin ES, Murphy EA, Khanna V, Neal JW, Chen CT, Kato S, Williams R, Bivona TG. Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies. Nat Commun. 2026 02 07; 17(1).

Publication Medline TA

Nat Commun

Date

2026-02-07